CASIA OpenIR  > 中国科学院分子影像重点实验室
A selenium- containing selective histone deacetylase 6 inhibitor for targeted in vivo breast tumor imaging and therapy
Tang, Chu1,2; Du, Yang2,3,4; Liang, Qian2; Cheng, Zhen5,6; Tian, Jie1,2,3,4
Source PublicationJOURNAL OF MATERIALS CHEMISTRY B
ISSN2050-750X
2019-06-14
Volume7Issue:22Pages:3528-3536
Corresponding AuthorCheng, Zhen(zcheng@stanford.edu) ; Tian, Jie(jie.tian@ia.ac.cn)
AbstractEarly detection and effective treatment are essential for the management of breast cancer, especially for triple-negative breast cancer (TNBC). However, current imaging methods and treatment strategies are ineffective because of the lack of efficient biomarkers and molecular targets. Thus, identifying novel biomarkers and their corresponding ligands is critical for controlling breast cancer. Histone deacetylase 6 (HDAC6) has emerged as a valid target for cancer therapy owing to its selective tumor inhibition and fewer side effects compared to pan-HDAC- and HDAC1-3 isoform-selective inhibitors. Here, a HDAC6-selective inhibitor, SelSA, was developed by utilizing a selenocyanide moiety instead of the conventional hydroxamic acid core, which showed 112-fold and 128-fold selective binding affinity for HDAC6 relative to HDAC1 and HDAC8. In vitro studies demonstrated that FITC-SelSA was specifically uptaken by both ER alpha(+) MCF-7 and TNBC MDA-MB-231 cells, with primarily cytoplasmic localization. SelSA reactivated ER alpha expression and sensitized TNBC cell responses to the antagonist tamoxifen, and displayed potent antitumor effects against both MCF-7 and MDA-MB-231 cells in vitro and tumor xenografts in vivo with no obvious side effects. Moreover, in in vivo near-infrared fluorescence imaging to assess SelSA biodistribution, the IRDye800CW-SelSA probe exhibited specific tumor targeting ability with high tumor-to-normal tissue contrast. The in vivo tumor treatment study revealed that SelSA possessed improved treatment efficacy and fewer side effects in both ER alpha(+) and TNBC tumors, compared to pan-HDAC inhibitors. Overall, our study indicated that the HDAC6 inhibitor SelSA is a highly promising candidate for targeted breast cancer imaging and therapy with clinical translational potential.
DOI10.1039/c9tb00383e
WOS KeywordESTROGEN-RECEPTOR ; HDAC6 INHIBITOR ; CANCER ; DESIGN ; TRICHOSTATIN ; FLUORESCENT ; GROWTH
Indexed BySCI
Language英语
Funding ProjectNational Key Research and Development Program of China[2017YFA0205200] ; National Key Research and Development Program of China[2016YFA0201401] ; National Key Research and Development Program of China[2016YFC0103702] ; National Key Research and Development Program of China[2016YFC0102000] ; National Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81527805] ; National Natural Science Foundation of China[61231004] ; National Natural Science Foundation of China[81601548] ; National Natural Science Foundation of China[81772011] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science & Technology Commission[Z161100002616022] ; China Postdoctoral Science Foundation[2017M613084] ; Shaanxi Postdoctoral Science Foundation[2017BSHEDZZ91]
Funding OrganizationNational Key Research and Development Program of China ; National Natural Science Foundation of China ; International Innovation Team of CAS ; Beijing Municipal Science & Technology Commission ; China Postdoctoral Science Foundation ; Shaanxi Postdoctoral Science Foundation
WOS Research AreaMaterials Science
WOS SubjectMaterials Science, Biomaterials
WOS IDWOS:000472230200004
PublisherROYAL SOC CHEMISTRY
Citation statistics
Cited Times:1[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Identifierhttp://ir.ia.ac.cn/handle/173211/26063
Collection中国科学院分子影像重点实验室
Corresponding AuthorCheng, Zhen; Tian, Jie
Affiliation1.Xidian Univ, Sch Life Sci & Technol, Minist Educ, Engn Res Ctr Mol & Neuro Imaging, Xian 710126, Shaanxi, Peoples R China
2.Chinese Acad Sci, CAS Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Inst Automat, Beijing 100190, Peoples R China
3.Beijing Key Lab Mol Imaging, Beijing 100190, Peoples R China
4.Univ Chinese Acad Sci, Beijing 100080, Peoples R China
5.Stanford Univ, Dept Radiol, MIPS, Stanford, CA 94305 USA
6.Stanford Univ, BioX Program, Canary Ctr, Stanford Canc Early Detect, Stanford, CA 94305 USA
Corresponding Author AffilicationChinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China
Recommended Citation
GB/T 7714
Tang, Chu,Du, Yang,Liang, Qian,et al. A selenium- containing selective histone deacetylase 6 inhibitor for targeted in vivo breast tumor imaging and therapy[J]. JOURNAL OF MATERIALS CHEMISTRY B,2019,7(22):3528-3536.
APA Tang, Chu,Du, Yang,Liang, Qian,Cheng, Zhen,&Tian, Jie.(2019).A selenium- containing selective histone deacetylase 6 inhibitor for targeted in vivo breast tumor imaging and therapy.JOURNAL OF MATERIALS CHEMISTRY B,7(22),3528-3536.
MLA Tang, Chu,et al."A selenium- containing selective histone deacetylase 6 inhibitor for targeted in vivo breast tumor imaging and therapy".JOURNAL OF MATERIALS CHEMISTRY B 7.22(2019):3528-3536.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Tang, Chu]'s Articles
[Du, Yang]'s Articles
[Liang, Qian]'s Articles
Baidu academic
Similar articles in Baidu academic
[Tang, Chu]'s Articles
[Du, Yang]'s Articles
[Liang, Qian]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Tang, Chu]'s Articles
[Du, Yang]'s Articles
[Liang, Qian]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.